Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Letai, Anthony G."" wg kryterium: Autor


Wyświetlanie 1-54 z 54
Tytuł :
Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways.
Autorzy :
Yoriko Saito
Yoshiki Mochizuki
Ikuko Ogahara
Takashi Watanabe
Leah Hogdal
Shinsuke Takagi
Kaori Sato
Akiko Kaneko
Hiroshi Kajita
Naoyuki Uchida
Takehiro Fukami
Shultz, Leonard D.
Shuichi Taniguchi
Osamu Ohara
Letai, Anthony G.
Fumihiko Ishikawa
Pokaż więcej
Temat :
ACUTE myeloid leukemia
GENETIC mutation
ALLELES
XENOGRAFTS
TARGETED drug delivery
Źródło :
Science Translational Medicine; 10/25/2017, Vol. 9 Issue 413, p1-12, 12p
Czasopismo naukowe
Tytuł :
Type II JAK2 Inhibitor NVP-CHZ868 Is Active in VivoAgainst JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)
Autorzy :
Li, Loretta S.
Wu, Shuo-Chieh
Kopp, Nadja
Montero, Joan
Ryan, Jeremy
Chapuy, Bjoern
Van der Zwet, Jordy C.
Layer, Jacob
Weigert, Oliver
Christie, Amanda L
Christodoulou, Alexandra N.
Liu, Huiyun
Yoda, Akinori
Hofmann, Francesco
Baffert, Fabienne
Vangrevelinghe, Eric
Gaul, Christoph
Radimerski, Thomas
Letai, Anthony G.
Weinstock, David M.
Pokaż więcej
Źródło :
Blood; November 2014, Vol. 124 Issue: 21 p3713-3713, 1p
Periodyk
Tytuł :
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Autorzy :
Guièze R; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France; Université Clermont Auvergne, EA7453 CHELTER, 63000 Clermont-Ferrand, France.
Liu VM; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA.
Rosebrock D; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jourdain AA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
Hernández-Sánchez M; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca, 37007 Salamanca, Spain; Servicio de Hematología, Hospital Universitario de Salamanca, 37007 Salamanca, Spain.
Martinez Zurita A; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Sun J; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Ten Hacken E; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA.
Baranowski K; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
Thompson PA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Heo JM; Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA.
Cartun Z; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
Aygün O; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Iorgulescu JB; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA.
Zhang W; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
Notarangelo G; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA.
Livitz D; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Li S; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
Biran A; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
Fernandes SM; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
Lako A; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ciantra ZB; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lawlor MA; Harvard Medical School, Boston, MA 02215, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02214, USA.
Keskin DB; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA.
Udeshi ND; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Wierda WG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Livak KJ; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
Letai AG; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
Neuberg D; Harvard Medical School, Boston, MA 02215, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Harper JW; Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA.
Carr SA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Piccioni F; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Ott CJ; Harvard Medical School, Boston, MA 02215, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02214, USA.
Leshchiner I; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Johannessen CM; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Doench J; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Mootha VK; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
Getz G; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02214, USA.
Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA. Electronic address: .
Pokaż więcej
Źródło :
Cancer cell [Cancer Cell] 2019 Oct 14; Vol. 36 (4), pp. 369-384.e13. Date of Electronic Publication: 2019 Sep 19.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Bridged Bicyclo Compounds, Heterocyclic/*pharmacology
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Mitochondria/*pathology
Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors
Sulfonamides/*pharmacology
Adult ; Aged ; Aged, 80 and over ; Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Apoptosis/drug effects ; Apoptosis/genetics ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Cell Line, Tumor ; Clonal Evolution/drug effects ; Disease Progression ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Energy Metabolism/drug effects ; Energy Metabolism/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Mice ; Middle Aged ; Mitochondria/drug effects ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Oxidative Phosphorylation/drug effects ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Sulfonamides/therapeutic use ; Treatment Outcome ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.
Autorzy :
Ariës IM; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Bodaar K; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Karim SA; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Chonghaile TN; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Deparment of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Hinze L; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Burns MA; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Pfirrmann M; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Degar J; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Landrigan JT; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Balbach S; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Pediatric Oncology, University Hospital Muenster, Muenster, Germany.
Peirs S; Center for Medical Genetics, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Menten B; Center for Medical Genetics, Ghent University, Ghent, Belgium.
Isenhart R; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Stevenson KE; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
Neuberg DS; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
Devidas M; Department of Biostatistics, University of Florida, Gainesville, FL.
Loh ML; Department of Pediatrics, University of California San Francisco, San Francisco, CA.
Hunger SP; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.
Teachey DT; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.
Rabin KR; Division of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX.
Winter SS; Cancer and Blood Disorders Department, Children's Minnesota, Minneapolis, MN.
Dunsmore KP; Department of Pediatrics, Carilion Children's, Roanoke, VA.
Wood BL; Department of Laboratory Medicine, University of Washington, Seattle, WA.
Silverman LB; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Sallan SE; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Van Vlierberghe P; Center for Medical Genetics, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Orkin SH; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Howard Hughes Medical Institute, Boston, MA.
Knoechel B; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Letai AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Gutierrez A; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA .; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Pokaż więcej
Źródło :
The Journal of experimental medicine [J Exp Med] 2018 Dec 03; Vol. 215 (12), pp. 3094-3114. Date of Electronic Publication: 2018 Nov 07.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Apoptosis*
Drug Resistance, Neoplasm*
Neoplasm Proteins/*metabolism
Polycomb Repressive Complex 2/*metabolism
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*metabolism
Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Female ; Gene Expression Regulation, Leukemic/drug effects ; Humans ; Male ; Mitochondria/genetics ; Mitochondria/metabolism ; Mitochondria/pathology ; Neoplasm Proteins/genetics ; Polycomb Repressive Complex 2/genetics ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Transcription, Genetic/drug effects ; Up-Regulation/drug effects
Czasopismo naukowe
    Wyświetlanie 1-54 z 54

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies